ASN 2017: Bridging AstraZeneca’s Expertise in Cardiovascular and Metabolic Diseases to Renal Risks and Outcomes

WRITTEN BY

Ludovic Helfgott, VP CVMD, GPPS, AstraZeneca

Despite scientific advancements, cardiovascular disease remains the number one cause of death globally, with high residual risk of recurrent events.1,2 A growing body of scientific evidence is uncovering the clinical overlap between cardiovascular, renal and metabolic diseases (CVMD) and their associated complications, which helps explain why reducing cardiovascular risk is so complex – yet in many cases, each condition is managed in isolation. With this growing unmet need in mind, we have developed a distinct approach at AstraZeneca focusing on jointly addressing patients’ cardio-renal-metabolic risks to change the science and treatment landscape.

Our team is proud of the breadth of AstraZeneca early- to late-stage data across cardiovascular, renal and metabolic diseases that is being presented at the upcoming American Society of Nephrology (ASN) Kidney Week 2017.  We will be presenting 33 abstracts investigating anaemia, hyperkalaemia and diabetic kidney disease, among other CVMD conditions and complications.

Renal disease is at the heart of this congress, and is a key part of our CVMD strategy. Our long-term ambition at AstraZeneca is to first manage chronic kidney disease (CKD) complications, including hyperkalaemia and anaemia; then stop the progression of disease and manage morbidity and mortality; and finally modify or reverse the disease itself. At Kidney Week, we will be sharing new real-world evidence data on the clinical and economic burden of hyperkalaemia, along with new Phase III data related to disease management.

I’m looking forward to meeting with external cardio-renal experts and my global colleagues on-the-ground at ASN this week – expanding and deepening our understanding of this complicated disease state and bringing this knowledge back to AstraZeneca. There’s huge promise for innovation in cardiovascular, renal and metabolic diseases, and together we will work toward developing therapies that deliver improved outcomes for millions of patients around the world.

 

1 World Health Organization. Cardiovascular diseases (CVDs). 2016. http://www.who.int/mediacentre/factsheets/fs317/en/. Accessed 21 September 2017.

2 Joshi PH, Martin SS, et al. The Remnants of Residual Risk. J Am Coll Cardiol. 2015; 65(21): 2276-2278.

Veeva ID: Z4-7804
Date of next review: October 2018